This site is intended for U.S. Healthcare Professionals only.

Privacy Policy


Introduction

We recognize that you value, and Omeros strives to respect, your privacy.  This Privacy Policy (“Policy”) describes how Omeros Corporation (“Omeros,” “we,” or “us”) collects, uses, and discloses information through the Websites that we operate and that link to or post this Policy (collectively, the “Websites”).  Please read the entire Privacy Policy before using our Websites.  By using the Websites, you consent to the terms of this Privacy Policy. 

Information Collection

You generally are not required to provide information about yourself when you visit the Websites.  However, we may ask you for some or all of the following types of information when you access various content or features, submit information to us, or directly contact us with questions or feedback:

  • Contact information, such as name and e-mail address;
  • Demographic information;
  • Geolocation information;
  • Communications preferences;
  • Search queries;
  • Correspondence and other information that you send to us; and
  • Additional information as otherwise described to you at the point of collection or pursuant to your consent.

We also may collect certain information automatically when you visit the Websites, including:

  • Your Internet Protocol (IP) address, which is the number automatically assigned to your computer whenever you access the Internet and that can sometimes be used to derive your general geographic area;
  • Other unique identifiers, including mobile device identification numbers;
  • Your browser type and operating system;
  • Sites you visited before and after visiting the Websites;
  • Pages you view and links you click on within the Websites;
  • Information collected through cookies, web beacons, and other technologies;
  • Information about your interactions with e-mail messages, such as the links clicked on and whether the messages were received, opened, or forwarded; and
  • Standard Server Log Information.

We may use cookies, pixel tags, and similar technologies to automatically collect this information.  Cookies are small bits of code that are stored by your computer’s web browser and that may automatically identify your browser to the Websites whenever your computer is used to visit the Websites.  Pixel tags are very small images or small pieces of data embedded in images, also known as "web beacons" or "clear GIFs,” that can recognize cookies, the time and date a page is viewed, a description of the page where the pixel tag is placed, and similar information from your computer or device.  By using the Websites, you consent to our use of cookies and similar technologies.  You can decide if and how your computer will accept a cookie by configuring your preferences or options in your browser.  However, if you choose to reject cookies and similar technologies, you may not be able to use certain online products, Websites or features on the Websites. 

Use of Information

We may use information that we collect through the Websites for a variety of purposes, including to:

  • Provide you with the Websites, services, email alerts, and information you request and respond to correspondence that we receive from you;
  • Contact you via email and otherwise about products and Websites that we think might be of interest to you;
  • Maintain or administer the Websites, perform business analyses, or for other internal purposes to improve the quality of our business, the Websites, and other products and Websites we offer;
  • Customize and personalize your use of the Websites; and
  • As otherwise described to you at the point of collection or pursuant to your consent.

Sharing of Information

We are committed to maintaining your trust, and we want you to understand when and with whom we may share the information we collect.

  • Service Providers: We may share your information with service providers that perform certain functions or Websites on our behalf (such as to host the Websites, fulfill requests, provide Websites, manage databases, provide patient assistance programs, perform analyses, provide customer service, or send communications for us).
  • Business Transfer: If we sell all or part of our business, or make a sale or transfer of assets, or are otherwise involved in a merger or business transfer, or in the unlikely event of bankruptcy, a business reorganization, or similar event, we may transfer your information as part of such transaction.
  • FDA and Prescribing Physicians: If you contact Omeros regarding your experience with one of our products, we may use the information you provide in submitting reports to regulatory agencies, such as the U.S. Food and Drug Administration, and as otherwise required of us by law.  We also may use the information to contact the prescribing physician to follow up regarding an event involving the use of our product.
  • Administrative or Legal Process: We may disclose your information to third parties in order to protect the legal rights, safety, and security of our organization, our corporate affiliates, subsidiaries, business partners, and the users of our Websites; enforce our Terms of Use; respond to and resolve claims or complaints; prevent fraud or for risk management purposes; and comply with or respond to law enforcement or legal process or a request for cooperation by a government or other entity, whether or not legally required.
  • Other Parties With Your Express or Implied Consent: We may share information with third parties when you consent to such sharing. 
  • Aggregate Information: We may share aggregate information, such as demographic and usage statistics, with advertisers, sponsors or other organizations.

In addition, we may allow third parties to place and read their own cookies, web beacons, Local Shared Objects, and similar technologies to collect information through the Websites.  For example, our third-party service providers may use these technologies to collect information that helps us with traffic measurement, research, and analytics.

Security

We have adopted security procedures to help protect against loss, misuse, and unauthorized access to the information you provide to us.  Please note that no data transmission or storage can be guaranteed to be 100% secure.  As a result, while we strive to protect your information and privacy, we cannot guarantee or warrant the security of any information you disclose or transmit to the Websites and cannot be responsible for the theft, destruction, or inadvertent disclosure of your information.

Children’s Privacy

The Websites are directed to a general audience. The Websites do not knowingly collect, use, or disclose personal information from children under the age of 13 without prior parental consent, except as permitted by the Children’s Online Privacy Protection Act (“COPPA”).  If we learn that we have collected personal information from a user under 13, we will promptly delete personal information collected from that user.

Your California Privacy Rights

We do not share your personally identifiable information with others for their direct marketing purposes. 

Some web browsers may transmit “do-not-track” signals to the Websites with which the user communicates.  Because of differences in how web browsers incorporate and activate this feature, it is not always clear whether users intend for these signals to be transmitted, or whether they even are aware of them.  Because there currently is no industry standard concerning what, if anything, Websites should do when they receive such signals, we currently do not take action in response to these signals.  If and when a final standard is established and accepted, we will reassess how to respond to these signals.  In some cases, third parties may be able to collect information about a user’s online activities over time and across different Websites when he or she uses our Websites. 

Links to Third Party Websites

The Websites may contain links to other websites or online websites that are operated and maintained by third parties and that are not under the control of or maintained by us.  Such links do not constitute an endorsement by us of those other Websites, the content displayed therein, or the persons or entities associated therewith.  This Privacy Policy does not apply to this third-party content.  We encourage you to review the privacy policies of these third-party Websites or Websites.

International Transfers

Please note that the Websites are directed towards users who reside in the United States.   Information that we collect may be stored and processed in the United States or in another country in which we, our agents, or our affiliated businesses maintain operations.  By using our products, Websites, and this site, you consent to any such transfer of information outside of your country.  While some of these countries may not offer the same level of privacy protection as your own, we commit to uphold the privacy protections as explained in this Policy.
 
Changes to Our Privacy Policy

We may amend this Privacy Policy at any time. Your continued use of the Websites after any modification to the Privacy Policy will constitute your acceptance of the new terms.

Questions

Please direct any questions regarding this Privacy Policy to: terms@omeros.com

Effective Date

This policy is effective as of March 9, 2016.

Omeros Corporation, Attention: General Counsel
201 Elliott Avenue West
Seattle, WA 98119

Important Safety Information

OMIDRIA® (phenylephrine and ketorolac injection) 1% / 0.3% must be added to irrigation solution prior to intraocular use.

OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.

Systemic exposure of phenylephrine may cause elevations in blood pressure.

Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other non-steroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma.

The most commonly reported adverse reactions at 2-24% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.

Use of OMIDRIA in children has not been established.

Please see the Full Prescribing Information for OMIDRIA.

You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Indications and Usage

OMIDRIA is added to ophthalmic irrigation solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.

OMEROS®, the OMEROS logo®, OMIDRIA®, and the OMIDRIA logo® are registered trademarks, and OMIDRIAssure™ is a trademark, of Omeros Corporation.
© Omeros Corporation 2016, all rights reserved. 2016-059

Close
References
  1. OMIDRIA [package insert]. Seattle, WA: Omeros Corporation; 2014.
  2. Flach AJ. Intraoperative floppy iris syndrome: pathophysiology, prevention, and treatment. Trans Am Ophthalmol Soc. 2009;107:234-239.
  3. Donnenfeld E. Current use of non-steroidal anti-inflammatory drugs in the treatment of ocular inflammation related to cataract surgery. Eur Ophthalmic Rev. 2012;6(3):173 177.
  4. Grob SR, Gonzalez-Gonzalez LA, Daly MK. Management of mydriasis and pain in cataract and intraocular lens surgery: review of current medications and future directions. Clin Ophthalmol. 2014;8:1281-1289.
  5. Katsev D, Katsev C, Pinnow J. Intracameral Ketorolac Concentration After Topical Ketorolac Administration Prior to Cataract Surgery. Electronic poster session presented at: American Society of Cataract and Refractive Surgery. 2015 ASCRS-ASOA Symposium and Congress; 2015 Apr 17-21; San Diego, CA.
  6. Lindstrom RL, Loden JC, Walters TR, et al. Intracameral phenylephrine and ketorolac injection (OMS302) for maintenance of intraoperative pupil diameter and reduction of postoperative pain in intraocular lens replacement with phacoemulsification. Clin Ophthalmol. 2014;8:1735-1744.
  7. Porela-Tiihonen S, Kaarniranta K, Kokki M, Purhonen S, Kokki H. A prospective study on postoperative pain after cataract surgery. Clin Ophthalmol. 2013;7:1429-1435.
  8. Myers WG, Edelhauser HF. Shortage of bisulfite-free preservative-free epinephrine for intracameral use. J Cataract Refract Surg. 2011;37(3):611.
  9. Cutler Peck CM, Brubaker J, Clouser S, et al. Toxic anterior segment syndrome: common causes. J Cataract Refract Surg. 2010;36(7):1073-1080.
  10. Tu EY. Balancing antimicrobial efficacy and toxicity of currently available topical ophthalmic preservatives. Saudi J Ophthalmol. 2014;28(3):182-187.
  11. US Food and Drug Administration. Compounding and the FDA: Questions and Answers. http://www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm339764.htm#approved. Accessed January 13, 2015.
  12. US Department of Health and Human Services. Guidance, Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act. Silver Spring, MD: Food and Drug Administration, Center for Drug Evaluation and Research (CDER); 2014. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM377052.pdf. Accessed August 28,2014.
  13. US Department of Health and Human Services. Guidance for Industry, Registration of Human Drug Compounding Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act. Silver Spring, MD: Food and Drug Administration, Center for Drug Evaluation and Research (CDER); 2013. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM377051.pdf. Accessed August 28, 2014.
  14. Compounding: inspections, recalls, and other actions. U.S. Food and Drug Administration Web site. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm339771.htm. Accessed January 5, 2015.
  15. Shaw J. Coping with the epinephrine shortage. EyeNet Magazine. June 2013;29-31. http://www.aao.org/publications/eyenet/201306/cataract.cfm?RenderForPrint=1. Accessed March 12, 2015.
  16. Department of Health and Human Services. Centers for Medicare & Medicaid Services. January 2015 Update of the Hospital Outpatient Prospective Payment System (OPPS). MLN Matters Number:MM9014. Revised December 23, 2014.
  17. Omeros, data on file
  18. Hovanesian JA, Sheppard JD, Trattler WB, et al. Intracameral phenylephrine and ketorolac (OMS302) during cataract surgery maintains intraoperative mydriasis and reduces postoperative ocular pain – integrated results from two pivotal phase 3 studies. J Cataract Refract Surg. In press 2015.